We conducted a global anti-corruption compliance risk assessment for a publicly-traded international medical device company. The results of this assessment, including the suggested compliance program improvements, were key factors in the DOJ’s decision to not criminally prosecute the company nor require any type of corporate monitoring. This compliance program risk assessment including extensive interviews of international personnel in various corporate functions, review of documents, forensic accounting analysis, and reporting our results to the DOJ.
FCPA Compliance Risk Assessment for Medical Device Company
You Also May Be Interested In:
Representation of Mallinckrodt Pharmaceuticals, a global pharmaceutical manufacturer, in numerous cases in courts across Tennessee, Kentucky, and Virginia
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.
Represented Boston Children’s Hospital with intellectual property, business, and government contracting issues associated with VaccineFinder